About: Impaired Growth during Childhood in Patients with Primary Ciliary Dyskinesia     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Primary ciliary dyskinesia (PCD) leads to recurrent/chronic respiratory infections, resulting in chronic inflammation and potentially in chronic pulmonary disease with bronchiectasis. We analyzed longitudinal data on body length/height and body mass index (BMI) for 29 children and young adults with PCD aging 1.5-24 years (median, 14.5) who had been diagnosed at the age of 0.5-17 years (median, 8). Of these, 10 carried pathogenic mutations in either DNAH5 or DNAI1. In children with PCD, body length/height progressively decreased from +0.40 +/- 0.24 SDS (the 1st birthday), +0.16 +/- 0.23 SDS (3 years old), and -0.13 +/- 0.21 SDS (5 years old) to -0.54 +/- 0.19 SDS (7 years old; P = 0.01 versus 0), -0.67 +/- 0.21 SDS (9 years old; P = 0.005 versus 0), -0.52 +/- 0.24 SDS (11 years old; P = 0.04 versus 0), and -0.53 +/- 0.23 SDS (13 years old; P = 0.03 versus 0). These results reflect low growth rates during the childhood growth period. Thereafter, heights stabilized up to the age of 17 years. The growth deterioration was not dependent on sex or disease severity but was more pronounced in DNAH5 or DNAI1 mutation carriers. BMI did not differ from population standards, which suggests that nutritional deficits are not the cause of growth delay. We conclude that PCD leads to chronic deprivation with significant growth deterioration during childhood.
  • Primary ciliary dyskinesia (PCD) leads to recurrent/chronic respiratory infections, resulting in chronic inflammation and potentially in chronic pulmonary disease with bronchiectasis. We analyzed longitudinal data on body length/height and body mass index (BMI) for 29 children and young adults with PCD aging 1.5-24 years (median, 14.5) who had been diagnosed at the age of 0.5-17 years (median, 8). Of these, 10 carried pathogenic mutations in either DNAH5 or DNAI1. In children with PCD, body length/height progressively decreased from +0.40 +/- 0.24 SDS (the 1st birthday), +0.16 +/- 0.23 SDS (3 years old), and -0.13 +/- 0.21 SDS (5 years old) to -0.54 +/- 0.19 SDS (7 years old; P = 0.01 versus 0), -0.67 +/- 0.21 SDS (9 years old; P = 0.005 versus 0), -0.52 +/- 0.24 SDS (11 years old; P = 0.04 versus 0), and -0.53 +/- 0.23 SDS (13 years old; P = 0.03 versus 0). These results reflect low growth rates during the childhood growth period. Thereafter, heights stabilized up to the age of 17 years. The growth deterioration was not dependent on sex or disease severity but was more pronounced in DNAH5 or DNAI1 mutation carriers. BMI did not differ from population standards, which suggests that nutritional deficits are not the cause of growth delay. We conclude that PCD leads to chronic deprivation with significant growth deterioration during childhood. (en)
Title
  • Impaired Growth during Childhood in Patients with Primary Ciliary Dyskinesia
  • Impaired Growth during Childhood in Patients with Primary Ciliary Dyskinesia (en)
skos:prefLabel
  • Impaired Growth during Childhood in Patients with Primary Ciliary Dyskinesia
  • Impaired Growth during Childhood in Patients with Primary Ciliary Dyskinesia (en)
skos:notation
  • RIV/00216208:11130/13:10209807!RIV14-MZ0-11130___
http://linked.open...avai/predkladatel
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, P(NT11469)
http://linked.open...iv/cisloPeriodika
  • 2013
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 79116
http://linked.open...ai/riv/idVysledku
  • RIV/00216208:11130/13:10209807
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • features; diagnosis; inflammation; disease; children; factor-i; adult height; cystic-fibrosis; longitudinal growth; lung transplantation (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [1B453A27AEEB]
http://linked.open...i/riv/nazevZdroje
  • International Journal of Endocrinology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • neuveden
http://linked.open...iv/tvurceVysledku
  • Lebl, Jan
  • Pohunek, Petr
  • Svobodová, Tamara
  • Zemková, Daniela
  • Djakow, Jana
  • Cipra, Adam
http://linked.open...ain/vavai/riv/wos
  • 000328793300001
issn
  • 1687-8337
number of pages
http://bibframe.org/vocab/doi
  • 10.1155/2013/731423
http://localhost/t...ganizacniJednotka
  • 11130
Faceted Search & Find service v1.16.116 as of Feb 22 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 81 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software